Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals

详细信息    查看全文

• 作者：Michael S. Sinha ; Aaron S. Kesselheim ; ^{akesselheim@partners.org}
• 关键词：Antibiotics ; FDA ; Market exclusivity
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2016
• 出版时间：15 December 2016
• 年：2016
• 卷：24
• 期：24
• 页码：6446-6451
• 全文大小：270 K
• 卷排序：24

文摘

Two primary regulatory mechanisms have been proposed to incentivize new antibiotic development: (1) changing Food and Drug Administration (FDA) approval processes to expedite antibiotic approval; and (2) offering enhanced possibilities for market exclusivity. Changes to the FDA regulatory approval process include greater reliance on surrogate endpoints such as biomarkers, use of noninferiority hypothesis designs for key preapproval clinical trials, and development of an expedited development track specific for antibiotics called the Limited Population pathway. The second strategy intended to encourage new antibiotic development has been to provide additional market exclusivity incentives based on regulatory approval. While these pathways have some positive attributes, they also present enhanced risks to patients associated with lower regulatory barriers and the market exclusivity incentives may not efficiently direct resources to the true origins of antibiotic innovation.